业绩总结 - 2020年TAVALISSE在美国的年销售额达到6170万美元，同比增长41%[6] - 2020年第四季度净产品销售为1770万美元，2020财年总净产品销售为6170万美元[61] - 2020年第四季度共发货1899瓶，2020财年总发货6651瓶[61] - 截至2020年12月31日，分销渠道中剩余984瓶[63] 用户数据 - 预计美国成人cITP患者人数为81,300人，其中约75%为使用过类固醇的患者[12][14] - TAVALISSE在全球市场的机会估计为9亿美元[19] 临床试验与研发 - 目前在进行的wAIHA临床试验已招募64名患者，目标为90名[6] - Fostamatinib在wAIHA的二期临床试验中显示出44%的反应率[22] - 目前正在进行的COVID-19相关临床研究包括一个Rigel主导的三期临床试验和两个二期临床试验[27] - Fostamatinib在COVID-19患者中的临床试验设计为随机1:1，包含两个治疗组，每组各30名住院患者[49] - NIH Phase 2临床试验的主要终点为29天内严重不良事件的累积发生率，次要终点包括多项评估疾病进展的临床相关指标[50] - 预计2021年4月将公布NIH Phase 2临床试验的初步数据[50] 市场扩张与前景 - TAVALISSE在欧洲的推出已在德国和英国进行，预计在未来18个月内逐步推广至整个欧洲[19] - TAVALISSE的FDA快车道认证为其在wAIHA市场提供了潜在的首发优势[22] - 预计TAVALISSE（Fostamatinib）的市场独占权将持续到2032年[57] - Rigel的RIPK1项目预计有10亿美元的市场机会[7] - 2021年预计将有多个催化剂，包括NIH Phase 2的顶线结果和Rigel Phase 3试验的结果[67] - Fostamatinib在COVID-19以外的肺炎和ARDS治疗中具有潜在开发机会[57] 负面信息 - 每年约有130万名患者因肺炎住院并面临急性呼吸窘迫综合症（ARDS）的风险[55] - Rigel预计在2021年第二季度获得以色列卫生部的批准[19]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 ...

FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 OR (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (St ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Commission file number 0‑29889 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 1180 Veterans Blvd. South San Francisco, California (Address of principal executive offices) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jur ...

WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-29889 Rigel Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 94-3248524 (Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or (I.R.S. Employer Identification No.) organization) 1180 Veterans Blvd. South San Francisco, CA 94080 (Address of principal executive offices) (Zip Code) (650) 624-1100 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10‑K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE Commission file number 0‑29889 RIGEL PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 1180 Veterans Blvd. So ...